Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Health Canada approves Biogen Idec Inc's Long-Acting ALPROLIX therapy for Hemophilia B


Monday, 24 Mar 2014 08:06am EDT 

Biogen Idec Inc:Says Health Canada approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B.The Health Canada approval of ALPROLIX is based on results from the global, Phase 3 B-LONG study, the l registrational study in hemophilia B ever completed.It demonstrated that ALPROLIX safely and effectively prevented, or reduced, bleeding episodes with prophylactic infusions given once weekly or once every 10-14 days in adults and adolescents with severe hemophilia B. 

Company Quote

343.04
1.8 +0.53%
29 Aug 2014